# Vaccine and Treatment Evaluation Units

> **NIH NIH UM1** · EMORY UNIVERSITY · 2022 · $318,891

## Abstract

Project Summary/Abstract
The currently NIAID-funded Vaccine and Treatment Evaluation Unit (VTEU) based at Emory University is
ideally positioned to implement the mission of
the Infectious Diseases Clinical Research Consortium (IDCRC)
.
The Emory VTEU is supported by Emory's rich scientific milieu with numerous synergistic grants and various
thematic research centers covering all IDCRC scientific priority areas. The Emory VTEU infrastructure relies on
two clinical research sites with a total of 16,000 square feet of clinical, laboratory, and pharmacy space and 83
faculty members and staff. Over the past decade as a funded VTEU, we have conducted 51 VTEU protocols,
served as lead on 25 trials, performed endpoint assays for 17 studies, and published 22 high impact papers.
We have enrolled ~3,000 participants, 55% are female and 37% from diverse racial and ethnic backgrounds
with a retention rate of ~93%. With its flexible infrastructure, the Emory VTEU demonstrated surge capacity to
contribute to pandemic influenza, Zika, Ebola, and biodefense efforts by prioritizing resources in funds and
staffing. The Emory VTEU will build on the current surge capacity by strengthening our partnership with the
Georgia Clinical and Translational Science Alliance and collaborating with well-established Emory international
partners on a protocol-specific basis. Additionally, to date, our VTEU has trained 28 fellows and junior faculty.
We will build on our significant record of accomplishment and advance the IDCRC mission by implementing
the following specific aims:
1. Engage a broad range of Emory scientists with expertise in established and newly emerging infectious
 diseases in the core science of the IDCRC including concept generation and protocol development.
2. Leverage our access to a unique and diverse population and state-of-the-art research infrastructure to
 implement all components of the IDCRC science, including study conduct, data quality control and
 assurance procedures, data management, and good clinical, laboratory, and pharmacy practices.
3. Optimize our operational flexibility to further enhance our ability to provide surge capacity to address
 emerging infectious diseases and pandemic response.
4. Expand our mentoring capacity and enhance career development opportunities for early stage
 investigators in the areas of vaccinology, infectious diseases diagnostics, therapeutics, and prevention.

## Key facts

- **NIH application ID:** 10493530
- **Project number:** 3UM1AI148576-03S3
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Nadine Georges Rouphael
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $318,891
- **Award type:** 3
- **Project period:** 2021-07-08 → 2023-03-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10493530

## Citation

> US National Institutes of Health, RePORTER application 10493530, Vaccine and Treatment Evaluation Units (3UM1AI148576-03S3). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10493530. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*